BiomX Inc. (NYSEAMERICAN:PHGE) Sees Significant Growth in Short Interest

BiomX Inc. (NYSEAMERICAN:PHGE) saw a large growth in short interest in May. As of May 15th, there was short interest totaling 197,532 shares, a growth of 116.4% from the April 30th total of 91,280 shares. Currently, 15.8% of the shares of the stock are short sold. Based on an average daily volume of 295,133 shares, the short-interest ratio is currently 0.7 days.

BiomX Price Performance

Shares of PHGE stock traded down $0.30 during trading on Friday, hitting $1.26. 2,155,916 shares of the stock traded hands, compared to its average volume of 17,516,138. BiomX has a 52-week low of $0.36 and a 52-week high of $14.71. The firm has a market capitalization of $12.79 million, a P/E ratio of -0.39 and a beta of 1.02. The firm’s fifty day moving average price is $2.07 and its 200-day moving average price is $3.56.

BiomX (NYSEAMERICAN:PHGE) last posted its earnings results on Wednesday, May 20th. The company reported $7.38 earnings per share (EPS) for the quarter. As a group, equities research analysts expect that BiomX will post -5.85 earnings per share for the current year.

Insiders Place Their Bets

In other BiomX news, Director Reuven Yeganeh sold 530,000 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $5.00, for a total value of $2,650,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 21.80% of the company’s stock.

Institutional Trading of BiomX

An institutional investor recently bought a new position in BiomX stock. Alyeska Investment Group L.P. bought a new stake in BiomX Inc. (NYSEAMERICAN:PHGE) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 1,590,738 shares of the company’s stock, valued at approximately $835,000. Alyeska Investment Group L.P. owned about 5.99% of BiomX at the end of the most recent reporting period. Institutional investors and hedge funds own 40.57% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright downgraded BiomX from a “buy” rating to a “hold” rating in a research note on Monday, March 9th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $26.00.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.